Natalie is a highly motivated leader who brings a wealth of experience, with a diverse background in oncology R&D spanning from early discovery through registration. She is passionate about building high-functioning teams and championing more effective ways of working. She previously spent more than a decade in various leadership roles at Johnson & Johnson (J&J), including head of the prostate cancer biomarker group, scientific licensing lead, and compound development team leader.

She played a pivotal role in the patient selection strategy, co-diagnostics, and clinical development of AKEEGA®, along with leading the scientific licensing for several potential strategic partnerships, including the acquisition of TARIS. In her role as a compound development team leader, she helped early development teams efficiently reach program milestones and go/no-go decision points.

Natalie holds a PhD in cell and molecular biology from the University of Pennsylvania School of Medicine, where she honed her passion for research and its application in drug development.